Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects

Trial Profile

A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ST 266 (Primary)
  • Indications Corneal disorders
  • Focus Therapeutic Use
  • Sponsors Noveome

Most Recent Events

  • 18 Sep 2020 Status changed from active, no longer recruiting to completed.
  • 22 Jul 2020 Status changed from recruiting to active, no longer recruiting.
  • 12 Jun 2020 According to a Noveome media release, data (as of data cutoff date, n=11) from this study was published today as an online presentation for the Association for Research in Vision and Ophthalmology (ARVO) 2020 Online Presentations and its associated platform, ARVOLearn.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top